2,6-Dichloromescaline
Pharmaceutical compound
From Wikipedia, the free encyclopedia
2,6-Dichloromescaline (2,6-CM), or dichloromescaline (DCL-M, DCM), also known as 2,6-dichloro-3,4,5-trimethoxyphenethylamine, is a psychedelic drug of the scaline family related to mescaline.[1][2][3] It is the 2,6-dichloro derivative of mescaline and the 6-chloro derivative of 2-chloromescaline.[1][2]
- None
| |
| Clinical data | |
|---|---|
| Other names | 2,6-CM; Dichloromescaline; DCL-M; DCl-M; 2,6-Dichloro-3,4,5-trimethoxyphenethylamine |
| Drug class | Serotonin receptor modulator; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C11H15Cl2NO3 |
| Molar mass | 280.15 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Interactions
Pharmacology
Pharmacodynamics
The drug shows affinity for serotonin receptors, including the serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors (Ki = 86 nM, 659 nM, and 801 nM, respectively).[1] These affinities were 35-fold, 7-fold, and 10-fold higher than those of mescaline, respectively.[1]
History
2,6-Dichloromescaline was first described in the scientific literature by 1977.[2][4] Its serotonin receptor affinities were determined by David E. Nichols and colleagues, with subsequent disclosure by Daniel Trachsel and colleagues via personal communication in 2013.[1] 2,6-Dichloromescaline has been encountered as a novel designer drug and is said to have been on the recreational market since at least the 1990s.[3] Relatedly, the properties and effects of 2,6-dichloromescaline in humans were described in The Entheogen Review in 1997, claiming a dose of approximately 10 mg orally to be robustly active.[5] However, a subsequent investigation concluded that this report was fabricated.[6]
Society and culture
Legal status
Canada
2,6-Dichloromescaline is not a controlled substance in Canada as of 2025.[7]